Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: a clinical benefit-oriented phase II study
2000
Gemcitabine and 5-Fluorouracil for Advanced Pancreatic Cancer
Sample size: 11
publication
Evidence: moderate
Author Information
Author(s): Matano E, Tagliaferri P, Libroia A, Damiano V, Fabbrocini A, De Lorenzo S, Bianco A R
Primary Institution: Università “Federico II”
Hypothesis
The combination of gemcitabine and 5-fluorouracil will provide clinical benefits to patients with advanced pancreatic cancer.
Conclusion
The combination of gemcitabine and 5-fluorouracil is well tolerated and provides symptomatic relief for most patients with advanced pancreatic cancer.
Supporting Evidence
- 7 out of 11 patients achieved a clinical benefit response.
- The mean time to loss of clinical benefit response was 26.5 weeks.
- No patients experienced severe toxicity.
Takeaway
This study tested a new treatment for sick patients with pancreatic cancer, and most of them felt better after using it.
Methodology
A two-stage phase II trial was conducted with 11 patients receiving gemcitabine and 5-fluorouracil.
Participant Demographics
Patients with symptomatic advanced pancreatic cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website